Sensus Healthcare (Boca Raton FL) received FDA approval to begin marketing its SRT-100 superficial radiotherapy system for the treatment of keloids, or scar tissue that forms over a wound whether from injury or surgical procedures. The system is used otherwise for treatment of non-melanoma skin cancers during in-office procedures.
The SRT-100 utilizes superficial X-rays to deliver radiation to the surface of the skin while causing no pain and not requiring anesthesia.
From the announcement:
“Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45 to 100%. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences,” stated Mark S. Nestor , MD, PhD of the Center for Cosmetic Enhancement in Aventura, FL.
SRT-100™ is an ideal treatment modality for non-melanoma skin cancers and keloids, thanks to its SharpBeam™ technology, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100™ is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.
Product page: SRT-100…
Announcement: Sensus Healthcare Receives FDA Clearance to Treat Keloids with the SRT-100™…
